Skin Cancer Clinical Trial
Official title:
Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology
Verified date | March 2022 |
Source | Brugmann University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Skin cancers are the most common of all cancers. Their incidence has increased sharply over the decades.This increase in incidence partly reflects an aging population and behavioral patterns such as repeated exposure to the sun. Indeed, exposure to UV rays is the predominant factor involved in the pathogenesis of these tumors, hence the fact that they mainly develop in photo-exposed regions such as the cephalic extremity. The objective of this study is to provide an epidemiological analysis of tumors in the populations of both CHU Brugmann and St Pierre hospitals.
Status | Completed |
Enrollment | 373 |
Est. completion date | July 28, 2021 |
Est. primary completion date | July 28, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Final diagnosis confirmed by pathological analysis, epidemiological and clinical information available from patients. Exclusion Criteria: Patients who have expressed a refusal to access their medical file or incomplete data will not be taken into account. |
Country | Name | City | State |
---|---|---|---|
Belgium | CHU Brugmann | Brussels |
Lead Sponsor | Collaborator |
---|---|
Brugmann University Hospital |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Age | Age of the patient at the time of diagnose | 5 minutes | |
Primary | Sex | Sex of the patient | 5 minutes | |
Primary | Name of the department in which the patient is followed | Ophthalmology-CHU Brugmann hospital or Dermatology-CHU Brugmann hospital or Ophthalmology- CHU St Pierre Hospital or Dermatology-CHU St Pierre Hospital | 5 minutes | |
Primary | Tumor anatomical location | Eyelids are distributed in their different regions: internal cantus and external cantus, upper eyelid and lower eyelid. Same for the face: ears, zygomatic, forehead, temples, cheeks, nose, upper lip, lower lip, chin, nasolabial fold, preauricular area, retroauricular area, brow bone. | 5 minutes | |
Primary | Tumor size | Tumor size in millimeters | 5 minutes | |
Primary | Laterality | Laterality: left, right, median | 5 minutes | |
Primary | Multiple or single tumor | Multiple or single tumor | 5 minutes | |
Primary | Primitive tumor or recidive | Primitive tumor or recidive | 5 minutes | |
Primary | Risk factor: phototype | Phototype 1 to 6 on the Fitzpatrick scale. The Fitzpatrick scale is a numerical classification schema for human skin color. Type 1 is pale skin that always burns, never tans and type 6 is deeply pigmented dark brown to darkest brown skin that never burns. | 5 minutes | |
Primary | Risk factor: immunosuppression (yes/no) | Pathogenic or iatrogenic, history of malignant skin tumors other than melanoma, personal or family history of melanoma | 5 minutes | |
Primary | Risk factor: keratosis | Actinic keratosis of the face | 5 minutes | |
Primary | Risk factor: solar exposition (yes/no) | Lived in a sunny European country> 1 year, lived in a sunny country outside Europe> 1 year, sunbed use> 1 session, history of solar erythema during childhood. | 5 minutes | |
Primary | Diagnosis | Time between the appearance of the tumor and the first consultation | 5 minutes | |
Primary | Locoregional extension report (yes/no) | Locoregional extension report (yes/no) | 5 minutes | |
Primary | Histological diagnosis of the tumor | Histological diagnosis of the tumor | 5 minutes | |
Primary | Healthy or invaded margins | Healthy or invaded margins | 5 minutes | |
Primary | Superficial or infiltrating tumor | Superficial or infiltrating tumor | 5 minutes | |
Primary | Diagnostic method | Diagnostic method: curettage, punch, biopsy, flattening | 5 minutes | |
Primary | Surgical management method | Biopsy resection, plasty, graft, second-line healing, enucleation, additional treatment: radiotherapy, immunotherapy, liquid nitrogen | 5 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05779423 -
Cryoablation+Ipilimumab+Nivolumab in Melanoma
|
Phase 2 | |
Terminated |
NCT01468818 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT01820234 -
Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event
|
N/A | |
Completed |
NCT00535769 -
Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
|
Phase 0 | |
Completed |
NCT00526032 -
Melanoma Detection by Oblique-Incidence Optical Spectroscopy
|
N/A | |
Completed |
NCT00588341 -
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
|
Phase 2 | |
Active, not recruiting |
NCT01447199 -
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
|
||
Enrolling by invitation |
NCT04758988 -
AI Augmented Training for Skin Specialists
|
N/A | |
Not yet recruiting |
NCT04534868 -
Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area
|
N/A | |
Recruiting |
NCT04138342 -
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
|
Phase 1 | |
Completed |
NCT03673917 -
Cosmetology Students and Skin Cancer
|
N/A | |
Recruiting |
NCT04341064 -
Sun-safe Habits Intervention and Education
|
Phase 3 | |
Completed |
NCT04206995 -
Cancer Sensing: Evaluation of Odour Sampling Techniques
|
||
Recruiting |
NCT05574101 -
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05860881 -
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
|
Phase 3 | |
Completed |
NCT05146622 -
Virtual Sun Safe Workplaces Ph I
|
||
Recruiting |
NCT05068310 -
Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
|
||
Recruiting |
NCT03889899 -
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
|
N/A |